Multiple System Atrophy ([MSA](/diseases/multiple-system-atrophy)), Progressive Supranuclear Palsy ([PSP](/diseases/progressive-supranuclear-palsy)), and Corticobasal Degeneration ([CBD](/diseases/corticobasal-degeneration)) constitute the three major atypical Parkinsonian disorders. While they share clinical features of Parkinsonism, these disorders have distinct pathological substrates, molecular mechanisms, and clinical trajectories. This comprehensive comparison elucidates their similarities and differences to inform accurate diagnosis and mechanistic understanding.
The three disorders belong to different proteinopathy categories:
| Disorder | Primary Proteinopathy | Tau Isoform | Filament Type |
|----------|----------------------|-------------|---------------|
| [MSA](/diseases/multiple-system-atrophy) | [α-Synuclein](/proteins/snca-protein) | N/A | N/A |
| [PSP](/diseases/progressive-supranuclear-palsy) | [4R Tau](/proteins/map-tau-protein) | 4R | Straight filaments |
| [CBD](/diseases/corticobasal-degeneration) | [4R Tau](/proteins/map-tau-protein) | 4R | Paired helical + straight |
Multiple System Atrophy ([MSA](/diseases/multiple-system-atrophy)), Progressive Supranuclear Palsy ([PSP](/diseases/progressive-supranuclear-palsy)), and Corticobasal Degeneration ([CBD](/diseases/corticobasal-degeneration)) constitute the three major atypical Parkinsonian disorders. While they share clinical features of Parkinsonism, these disorders have distinct pathological substrates, molecular mechanisms, and clinical trajectories. This comprehensive comparison elucidates their similarities and differences to inform accurate diagnosis and mechanistic understanding.
The three disorders belong to different proteinopathy categories:
| Disorder | Primary Proteinopathy | Tau Isoform | Filament Type |
|----------|----------------------|-------------|---------------|
| [MSA](/diseases/multiple-system-atrophy) | [α-Synuclein](/proteins/snca-protein) | N/A | N/A |
| [PSP](/diseases/progressive-supranuclear-palsy) | [4R Tau](/proteins/map-tau-protein) | 4R | Straight filaments |
| [CBD](/diseases/corticobasal-degeneration) | [4R Tau](/proteins/map-tau-protein) | 4R | Paired helical + straight |
Key insight: [MSA](/diseases/multiple-system-atrophy) is a synucleinopathy while [PSP](/diseases/progressive-supranuclear-palsy) and [CBD](/diseases/corticobasal-degeneration) are [4R tauopathies](/mechanisms/4r-tauopathies-neuroimmune-comparison). This fundamental difference drives distinct pathogenesis and informs therapeutic approaches [Kovács et al., Comparative neuropathology of atypical parkinsonian disorders (2023)](https://doi.org/10.1007/s00401-023-02540-9).
Multiple System Atrophy:
| Feature | MSA | PSP | CBD |
|---------|-----|-----|-----|
| Autonomic failure | Prominent early | Late/mild | Late/mild |
| Eye movements | Rarely vertical gaze palsy | Vertical supranuclear gaze palsy | Variable |
| Motor onset | Symmetric | Symmetric | Asymmetric |
| Ataxia | Common (especially cerebellar type) | Rare | Rare |
| Apraxia | Uncommon | Uncommon | Common |
| Cortical sensory loss | Absent | Absent | Common |
MSA:
| Brain Region | MSA | PSP | CBD |
|-------------|-----|-----|-----|
| Basal ganglia | ++ | +++ | +++ |
| Brainstem | +++ | ++ | + |
| Cerebellum | ++ | + | ± |
| Cerebral cortex | + | ++ | +++ |
| Spinal cord | ++ | + | ± |
| White matter | +++ | ++ | ++ |
+ = mild involvement, ++ = moderate, +++ = severe, ± = variable
[Dickson et al., Neuropathology of atypical parkinsonism (2022)](https://doi.org/10.1038/s41582-022-00687-2)
MSA - α-Synucleinopathy:
| MRI Feature | MSA | PSP | CBD |
|------------|-----|-----|-----|
| Pontine atrophy | +++ | ++ | + |
| Middle cerebellar peduncle hyperintensity | ++ | ± | ± |
| "Hummingbird" sign | - | +++ | - |
| Asymmetric cortical atrophy | - | - | +++ |
| Hot cross bun sign | ++ | ± | ± |
[Grazia et al., Imaging biomarkers in atypical parkinsonism (2024)](https://doi.org/10.1212/WNL.0000000000208901)
| Biomarker | MSA | PSP | CBD |
|-----------|-----|-----|-----|
| Neurofilament light chain (NfL) | Elevated | Elevated | Elevated |
| Total tau | Normal | Normal/elevated | Normal/elevated |
| Phospho-tau (181) | Normal | May be elevated | May be elevated |
| α-Synuclein RT-QuIC | Positive (variable) | Negative | Negative |
[Kurt et al., Biomarkers in atypical parkinsonian disorders (2023)](https://doi.org/10.1212/WNL.0000000000207201)
| Treatment | MSA | PSP | CBD |
|-----------|-----|-----|-----|
| Levodopa | Minimal response | Minimal response | Minimal response |
| Dopamine agonists | Limited | Limited | Limited |
| Botulinum toxin | Limited | Limited | Good (dystonia) |
| Speech therapy | Limited | Limited | Variable |
Based on distinct pathomechanisms:
MSA (Second Consensus Criteria 2022):
Recent advances in tau PET radioligands have enabled in vivo visualization of tau pathology in atypical parkinsonian disorders[@koga2024]:
| Ligand | Target | MSA | PSP | CBD | Key Findings |
|--------|--------|-----|-----|-----|-------------|
| Flortaucipir (18F-AV-1451) | 3R/4R tau | - | +++ | ++ | PSP shows highest uptake in basal ganglia and brainstem |
| PI-2620 | 4R tau specific | - | +++ | +++ | Higher selectivity for 4R tauopathies |
| MK-6240 | 3R tau | - | - | - | Not useful for 4R tauopathies |
Key observations from tau PET studies:
Emerging molecular classification integrates neuropathology with fluid and imaging biomarkers[@kovacs2024][@jellinger2025]:
| Molecular Type | Pathological Features | Clinical Phenotype | Biomarker Profile |
|----------------|----------------------|-------------------|-------------------|
| PSP-type | Tufted astrocytes, globose tangles, 4R tau straights | Richardson syndrome, PSP-P | Elevated p-tau181, NfL |
| CBD-type | Astrocytic plaques, ballooned neurons, coiled bodies | CBS, CBD | Elevated NfL, subtle p-tau181 |
| AGD-type | Argyrophilic grains, coiled bodies | AGD, PSP-PAGF | Elevated p-tau231 |
| GGT-type | Glial tau inclusions, 4R tau | GGT, PSP-CBS | Unique fluid profile |
| Subtype | Alpha-synuclein Distribution | Clinical Pattern |
|---------|-----------------------------|-----------------|
| MSA-C | GCIs predominant in cerebellum/brainstem | Cerebellar ataxia dominant |
| MSA-P | NCIs and GCIs in striatum | Parkinsonism dominant |
| Mixed | Balanced distribution | Intermediate phenotype |
The natural history of atypical parkinsonian disorders differs substantially[@fathy2024]:
| Milestone | MSA | PSP | CBD |
|-----------|-----|-----|-----|
| Mean disease duration | 6-9 years | 7-9 years | 6-8 years |
| Time to wheelchair | 3-4 years | 3-5 years | 3-5 years |
| Time to falls (>50%) | 2-3 years | 1-2 years | 2-3 years |
| Cognitive decline onset | 2-4 years | 2-4 years | 1-3 years |
| Death from onset | 7.5 years | 8.5 years | 7 years |
Key distinguishing features:
Designing trials for these overlapping disorders requires careful consideration[@botzel2024]:
| Biomarker | Utility in Trial Design |
|-----------|------------------------|
| Tau PET | Enrichment for 4R tauopathies; exclusion of MSA |
| Neurofilament light chain (NfL) | Prognostic stratification; monitoring |
| RT-QuIC | Exclusion of MSA when synucleinopathies included |
| Genetic testing | MAPT, GBA, SNCA for stratification |
While MSA, PSP, and CBD share the clinical phenotype of atypical parkinsonism, they represent distinct clinicopathological entities. MSA is fundamentally an α-synucleinopathy with primary oligodendrocyte involvement, while PSP and CBD are 4R tauopathies targeting different neuronal populations and circuits. Understanding these differences is critical for: